At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.

Health Care

Life Sciences

Therapeutics

Avid Radiopharmaceuticals

Daniel M Skovronsky

Marybeth Devine

Amanda Morris

Robert Morrison

Kelly Conway

Carey Horchler

Anne McGeehan

Lisaann Trembath

David Wilson

Luckens Osias

Ian Halvorsen

Christine Gallagher

Caitlin Pearson

The Quality Assurance and Control team at Avid Radiopharmaceuticals is responsible for ensuring the highest standards of quality and compliance throughout the development and manufacturing processes of molecular imaging agents. This team conducts rigorous testing, validation, and audits to uphold Good Manufacturing Practices (GMP) and Good Clinical Practices (GCP), thereby ensuring the safety and efficacy of products aimed at early detection and management of chronic diseases. Their work is crucial in maintaining regulatory compliance and fostering trust in Avid's innovative imaging solutions.

Quality Assurance and Control

Operations and Support

Research and Development

Clinical Operations and Management

Quality Assurance and Control

About

Team members

Other teams at Avid Radiopharmaceuticals

Operations and Support

Research and Development

Clinical Operations and Management